Skip to main navigation
  • Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
VectivBio

VectivBio

Transforming Lives

Site - Header Menu

  • About Us
    • Management Team
    • Board Members
    • Investors
    • Partners
  • Our Focus
    • Our Science
    • Our Pipeline
    • Our Clinical Trials
  • Investors & Media
    • Overview
    • News & Media
    • Events & Presentations
    • Annual General Meeting
    • Financial Information
    • Stock Information
    • Corporate Governance
    • Shareholder Resources
  • Contact Us
    • Careers

Press Releases

Jun 29, 2022

VectivBio Announces Closing of $54 Million Aggregate Financing

BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has closed each of its previously announced public offering of ...

Read More

Jun 14, 2022

VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares

Combined Gross Proceeds from Public Offering and Private Sale Total $50 Million BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare ...

Read More

Jun 14, 2022

VectivBio Announces Launch of Public Offering of Ordinary Shares

BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a follow-on public offering of its ordinary ...

Read More

Jun 09, 2022

VectivBio Publishes Invitation to the Annual General Meeting

BASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2022 Annual General Meeting, which will ...

Read More

Jun 02, 2022

VectivBio Announces First Two Patients Dosed in Phase 2 STARGAZE Study of Apraglutide for the Treatment of Acute Graft-versus-Host Disease

– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, demonstrating broad potential of this next generation GLP-2 ...

Read More

May 09, 2022

VectivBio to Participate at the Bank of America 2022 Healthcare Conference

BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive ...

Read More

Apr 21, 2022

VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

Arena Pharmaceuticals and Actelion veteran brings deep industry experience as VectivBio prepares for key upcoming catalysts BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel ...

Read More

Apr 07, 2022

VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase ...

Read More

Mar 30, 2022

VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in Japan Loan facility established with ...

Read More

Mar 29, 2022

VectivBio Presents New Clinical Data Supporting Apraglutide for Treatment of Short Bowel Syndrome with Intestinal Failure (SBS-IF) Patients Who Have Renal Dysfunction at the 2022 American Society of Parenteral and Enteral Nutrition Conference

-- Apraglutide well-tolerated and does not require dose-adjustment in patients with severe renal disease -- -- Results demonstrate potential to reach 28% of SBS-IF patients with renal dysfunction who are underserved by currently available therapies -- BASEL, Switzerland, March 29, 2022 (GLOBE ...

Read More

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 12

Primary Sidebar

INVESTORS & MEDIA

  • Overview
  • News & Media
    • Press Releases
  • Events & Presentations
  • Annual General Meeting
  • Financial Information
    • SEC Filings
    • Annual Reports
    • Quarterly Reports
  • Stock Information
    • Historical Stock Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board Members
    • Committee Composition
  • Shareholder Resources
    • FAQs
    • Email Alerts
    • Contact IR
    • RSS Feeds

Site - Shareholder Tools

Email Alerts Print Search

IR CONTACT

ir@vectivbio.com

 

Footer

Site - Footer Menu Left

VectivBio

Site - Footer Menu Center

Terms of Use Privacy Policy

Copyright © VectivBio AG, 2022. All Rights Reserved.

Site - Footer Menu Right

  • About Us
  • Our Focus
  • Investors & Media
  • Contact Us

Site - Header Menu

  • About Us
    • Management Team
    • Board Members
    • Investors
    • Partners
  • Our Focus
    • Our Science
    • Our Pipeline
    • Our Clinical Trials
  • Investors & Media
    • Overview
    • News & Media
    • Events & Presentations
    • Annual General Meeting
    • Financial Information
    • Stock Information
    • Corporate Governance
    • Shareholder Resources
  • Contact Us
    • Careers